First-in-human evaluation of [99mTc]Tc-(HE)3-G3, a novel DARPin-based agent for imaging of HER2 expression in breast cancer

Published on May 1, 2021in Nuclear Medicine and Biology2.396
· DOI :10.1016/S0969-8051(21)00295-X
Vladimir Tolmachev61
Estimated H-index: 61
Olga Bragina4
Estimated H-index: 4
+ 6 AuthorsVladimir M. Chernov7
Estimated H-index: 7
📖 Papers frequently viewed together
7 Authors (Lingzhou Zhao, ..., Wenhua Huang)
5 Authors (Fan-Lin Kong, ..., David J. Yang)
Cited By2
#1Tianqi Xu (Uppsala University)H-Index: 2
#2Anzhelika Vorobyeva (Uppsala University)H-Index: 11
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 11 authors...
Efficient treatment of disseminated ovarian cancer (OC) is challenging due to its heterogeneity and chemoresistance. Overexpression of human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM) in approx. 30% and 70% of ovarian cancers, respectively, allows for co-targeted treatment. The clinical efficacy of the monoclonal antibody trastuzumab in patients with HER2-positive breast, gastric and gastroesophageal cancers makes it readily available as the HER2-targ...
1 CitationsSource
#1Sergey M. Deyev (Tomsk Polytechnic University)H-Index: 29
#2Tianqi Xu (Uppsala University)H-Index: 2
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 13 authors...
The epithelial cell adhesion molecule (EpCAM) is intensively overexpressed in 40–60% of prostate cancer (PCa) cases and can be used as a target for the delivery of drugs and toxins. The designed ankyrin repeat protein (DARPin) Ec1 has a high affinity to EpCAM (68 pM) and a small size (18 kDa). Radiolabeled Ec1 might be used as a companion diagnostic for the selection of PCa patients for therapy. The study aimed to investigate the influence of radiolabel position (N- or C-terminal) and compositio...
1 CitationsSource